Sort publications on year
-
Pharmaco-Economics
Ready-to-use pre-filled syringes of atropine for anaesthesia care in French hospitals – a budget impact analysis.
BENHAMOU D, PIRIOU V, DE VAUMAS C, ALBALADEJO P, MALINOVSKY JM, DOZ M, LAFUMA A, BOUAZIZ H.
Anaesth Crit Care Pain Med - 2016 ;
-
Pharmaco-Economics
Cost-effectiveness model comparing dual-mobility to fixed-bearing designs for total hip replacement in France.
EPINETTE JA, LAFUMA A, ROBERT J, DOZ M
Orthop Traumatol Surg Res. ; 2016;102(2):143-148
-
Pharmaco-Economics
Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals
LE MONNIER A, DUBURCQ A, ZAHAR JR, CORVEC S, GUILLARD T, CATTOIR V, WOERTHER PL, FIHMAN V, LALANDE V, JACQUIER H, MIZRAHI A, FARFOUR E, MORAND P, MARCADĂ G, COULOMB S, TORRETON E, FAGNANI F, BARBUT F, GMC STUDY GROUP
J Hosp Infect ; 2015;91:117-122
-
Pharmaco-Economics
Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study.
DARBĂ J, KASKENS L, DETOURNAY B, KERN W, NICOLUCCI A, OROZCO-BELTRAN D, RAMIREZ DE ARELLANO A
ClinicoEconomics and Outcomes Research ; 2015;7:163-171
-
Pharmaco-Economics
Increased Costs Due To Myocardial Infarction (Mi) In France: An Observational Analysis Using A Claims Database.
BLIN P, PHILIPPE F, LAURENDEAU C, BOUEE S, GOURMELEN J, LEVY BACHELOT L, LEPROUST S, STEG PG.
Value Health ; 2015;18(7):A386
-
Pharmaco-Economics
Utilisation de lâinsuline en France : les chiffres clĂ©s
DETOURNAY B
Diabétologie Pratique - congrÚs 1er avril 2015 ;
-
Pharmaco-Economics
Prise en charge et coûts de la bronchopneumopathie chronique obstructive en France en 2011
LAURENDEAU C, CHOUAID C, ROCHE N, TERRIOUX P, GOURMELEN J , DETOURNAY B
Rev Mal Respir ; 2015;32:682-91
-
Pharmaco-Economics
Le coĂ»t de lâinsulinothĂ©rapie en France chez les patients diabĂ©tiques de type 2
DETOURNAY B, BUREAU I, GOURMELEN J
MĂ©decine des maladies MĂ©taboliques ; 2015;9:3S30-3S33
-
Pharmaco-Economics
Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals
LE MONNIER A, DUBURCQ A, ZAHAR JR, CORVEC S, GUILLARD T, CATTOIR V, WOERTHER PL, FIHMAN V, LALANDE V, JACQUIER H, MIZRAHI A, FARFOUR E, MORAND P, MARCADĂ G, COULOMB S, TORRETON E, FAGNANI F, BARBUT F, GMC STUDY GROUP
J Hosp Infect ; 2015;91:117-122
-
Pharmaco-Economics
Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study
DARBĂ J, KASKENS L, DETOURNAY B, KERN W, NICOLUCCI A, OROZCO-BELTRAN D, RAMIREZ DE ARELLANO A
2015 - ClinicoEconomics and Outcomes Research ; 7 : 163-71
-
Pharmaco-Economics
A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical
DEMARTEAU N, DETOURNAY B, TEHARD B, EL HASNAOUI A, STANDAERT B
Int J Public Health ; 2011;56(2):153-62
-
Pharmaco-Economics
The cost of managing HIV infection in highly treatment-experienced, HIV-Infected adults in France
COLIN X, LAFUMA A, COSTAGLIOLA D, LANG JM, GUILLON P
Pharmacoeconomics ; 2010;28(S1):59-68
-
Pharmaco-Economics
Modelling the budget impact of Darunavir in the treatment of highly treatment-experienced, HIV-Infected adults in France
COLIN X, LAFUMA A, COSTAGLIOLA D, SMETS E, MAUSKOPF J, GUILLON P
Pharmacoeconomics ; 2010;28(S1):183-197
-
Pharmaco-Economics
Lifetime costs and effectiveness of ReSTOR compared with a monofocal IOL and Array-SA40 in the Netherlands
DE VRIES NE, LAURENDEAU C, LAFUMA A, BERDEAUX G, NUIJTS RM
Eye ; 2010;24(4):663-672
-
Pharmaco-Economics
Inpatient costs of endophthalmitis evaluated for the whole of France
COLIN X, BERDEAUX G, LAFUMA A, SALVANET-BOUCHARA A, KODJIKIAN L
Appl Health Econ Health Policy ; 2010;8(1):53-60
  Â